METHIMAZOLE Drug Patent Profile
✉ Email this page to a colleague
When do Methimazole patents expire, and when can generic versions of Methimazole launch?
Methimazole is a drug marketed by Bionpharma, Chartwell Rx, Discovery Therap, Heritage Pharma, Macleods Pharms Ltd, Mylan, Qingdao Baheal Pharm, Rising, and Sun Pharm Inds Inc. and is included in nine NDAs.
The generic ingredient in METHIMAZOLE is methimazole. There are three drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the methimazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methimazole
A generic version of METHIMAZOLE was approved as methimazole by MYLAN on March 29th, 2000.
Summary for METHIMAZOLE
Recent Clinical Trials for METHIMAZOLE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Case Comprehensive Cancer Center | Phase 2 |
Nanjing First Hospital, Nanjing Medical University | Early Phase 1 |
Beijing Tongren Hospital | Early Phase 1 |
Pharmacology for METHIMAZOLE
Drug Class | Thyroid Hormone Synthesis Inhibitor |
Mechanism of Action | Thyroid Hormone Synthesis Inhibitors |